FDA Inspection 832888 — Contacare Ophthalmics & Diagnostics

Contacare Ophthalmics & Diagnostics — FEI 3006217304

The FDA completed an inspection of Contacare Ophthalmics & Diagnostics on April 29, 2013 in Dabhasa. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 19 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 29, 2013
Fiscal Year
2013
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Dabhasa (India)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
111121 CFR 211.25(a)Training , Education , Experience overall
113321 CFR 211.25(a)GMP Training Frequency
121521 CFR 211.67(b)Written procedures not established/followed
135821 CFR 211.100(b)SOPs not followed / documented
145121 CFR 211.113(b)Procedures for sterile drug products
180921 CFR 211.160(a)Following/documenting laboratory controls
189021 CFR 211.165(e)Test methods
192021 CFR 211.166(a)(3)Valid stability test methods
200921 CFR 211.188Prepared for each batch, include complete information
203121 CFR 211.194(a)Complete test data included in records
203421 CFR 211.194(d)Laboratory equipment calibration records
261921 CFR 211.198(b)(2)Complaint Investigation/Follow-Up Findings
358321 CFR 211.110(a)Written in-process control procedures
360221 CFR 211.160(a)Deviations from laboratory control requirements
360321 CFR 211.160(b)Scientifically sound laboratory controls
430221 CFR 211.56(b)Written sanitation procedures not followed
431421 CFR 211.84(d)(2)Reports of Analysis (Components)
441321 CFR 211.194(a)(8)Second person sign off